Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection

Fineline Cube Nov 1, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...

Company Drug

Shenzhen Chipscreen Biosciences Gets NMPA Approval for Phase I Study of CS32582 in Psoriasis

Fineline Cube Nov 1, 2023

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced that it...

Company Deals

Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round

Fineline Cube Nov 1, 2023

Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million)...

Company Deals

ImmuXell Biotech Secures Over RMB 100 Million in Series A Funding for Cell Therapy Development

Fineline Cube Nov 1, 2023

ImmuXell Biotech Co., Ltd, a Shanghai-based cell therapy developer, has reportedly secured over RMB 100...

Company Drug

Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study

Fineline Cube Nov 1, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...

Company Drug

Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Nov 1, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...

Company

Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report

Fineline Cube Nov 1, 2023

US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for...

Company Drug

Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment

Fineline Cube Nov 1, 2023

The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...

Company Deals

AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib

Fineline Cube Nov 1, 2023

China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...

Company Drug

Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial

Fineline Cube Nov 1, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...

Company Deals

BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences

Fineline Cube Nov 1, 2023

Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...

Drug

Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion

Fineline Cube Nov 1, 2023

Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...

Policy / Regulatory

Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI

Fineline Cube Nov 1, 2023

The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a...

Company Medical Device

Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China

Fineline Cube Nov 1, 2023

Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received...

Company Deals

Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals

Fineline Cube Nov 1, 2023

China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...

Company Deals

Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform

Fineline Cube Oct 31, 2023

Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...

Company Deals

Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor

Fineline Cube Oct 31, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...

Company Drug

Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Oct 31, 2023

Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...

Company Drug

Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia

Fineline Cube Oct 31, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Oct 31, 2023

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...

Posts pagination

1 … 494 495 496 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.